Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by lonc17on Nov 30, 2023 2:12pm
235 Views
Post# 35761685

Options

Options
Poor Matt Coffey. Greed may have got the best of him now.

Back a few years ago he went feeding at the trough and awarded himself 175,000 options with an exercise price of $1.45 CDN.

They expire in eleven days and they are in the money.

So he will pay $254,000 to convert these options to shares. And he will hold all of these shares if he is an honorable person. Else the message to the market is "get the hell out of ONC as fast as you can because even the CEO thinks it is overvalued."

And so he will be stuck with 175,000 in a lousy company that has very little chance of ever delivering on a Phase 3 without massive dilution and probably a reverse split (agian) sometime in the next year.

Almost no chance of MC profiting on this particular visit to the trough.
<< Previous
Bullboard Posts
Next >>